SymbolACAD
NameACADIA PHARMACEUTICALS INC
SectorHEALTH CARE
RegionUNDEFINED
IndustryPharmaceutical Preparations
Address12830 EL CAMINO REAL, SAN DIEGO, CA 92130
Telephone858-558-2871
Fax
Email
Websitehttps://www.acadia.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinsons, Alzheimers, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The companys patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Additional info from NASDAQ:
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinsons, Alzheimers, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The companys patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

2026-04-17 13:05

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Read more
2026-04-15 20:05

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Read more
2026-04-07 23:57

Schneyer Mark C. 🟡 adjusted position in 2.7K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $22.20 Transaction Date: Apr 05, 2026 | Filing ID: 000005

Read more
2026-04-07 23:55

Kihara James 🟡 adjusted position in 1.0K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $22.20 Transaction Date: Apr 05, 2026 | Filing ID: 000005

Read more
2026-04-07 13:05

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Read more
2026-03-27 00:00

Owen Adams Catherine 🟡 adjusted position in 11.6K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.47 Transaction Date: Mar 24, 2026 | Filing ID: 000003

Read more
2026-03-27 00:00

Rhodes Jennifer J 🟡 adjusted position in 3.8K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.47 Transaction Date: Mar 24, 2026 | Filing ID: 000005

Read more
2026-03-27 00:00

Thompson Elizabeth H.Z. 🟡 adjusted position in 3.4K shares (1 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.47 Transaction Date: Mar 24, 2026 | Filing ID: 000003

Read more
2026-03-27 00:00

Kihara James 🟡 adjusted position in 1.9K shares (2 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.73 Transaction Date: Mar 24, 2026 | Filing ID: 000003

Read more
2026-03-27 00:00

Schneyer Mark C. 🟡 adjusted position in 7.4K shares (2 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $21.72 Transaction Date: Mar 24, 2026 | Filing ID: 000003

Read more